Department of Ophthalmology, University of Bonn, Bonn, Germany.
Acta Ophthalmol. 2012 Feb;90(1):68-70. doi: 10.1111/j.1755-3768.2009.01842.x. Epub 2010 Feb 16.
To determine the concentration of unbound bevacizumab in untreated fellow eyes after contralateral intravitreal injection of bevacizumab.
A total of 18 eyes received intravitreal injections of 1.5 mg bevacizumab. Nine probes were obtained in the injected eye and nine in the fellow eye. Each group contained three individual eyes. Aqueous humour samples were obtained during uneventful phacoemulsification at three intervals 1-7 days (group a), 8-12 days (group b) or 13-28 days (group c).
In untreated fellow eyes, the concentration of unbound bevacizumab was below the detectable limit of the ELISA (5 ng/ml in all samples). The mean concentration of unbound bevacizumab in the injected eye declined from 28.6 μg/ml (group a), 16.5 μg/ml (group b) to 7.4 μg/ml (group c).
There are no pharmacological indications for a significant concentration of unbound bevacizumab in the anterior chamber of contralateral eyes in humans.
确定对侧玻璃体内注射贝伐单抗后未经治疗的对侧眼游离贝伐单抗的浓度。
共 18 只眼接受了 1.5 mg 贝伐单抗的玻璃体内注射。在注射眼和对侧眼各获得 9 个探针。每组包含三个单独的眼睛。在无并发症的超声乳化期间，在三个时间点（a 组 1-7 天，b 组 8-12 天或 c 组 13-28 天）获得房水样本。
在未经治疗的对侧眼中，游离贝伐单抗的浓度低于 ELISA 的检测下限（所有样本均为 5ng/ml）。注射眼的游离贝伐单抗浓度从 28.6μg/ml（a 组）、16.5μg/ml（b 组）降至 7.4μg/ml（c 组）。
在人类中，对侧眼前房内不存在游离贝伐单抗的显著浓度的药理学指征。
